Zebrafish as a New In Vivo Model to Study Angiogenesis in Neuroendocrine Tumors (NET) Abstract #1127

Introduction: Zebrafish is a powerful model to study human diseases, including cancer.
Aim(s): A novel in vivo angiogenesis assay based on the injection of human NET cell lines (TT, MZ-CRC1, DMS79 and PC3) and primary NET cell cultures has been developed in Tg(fli1:EGFP)y1 zebrafish embryos, in which the fluorescent protein EGFP is expressed in the vascular tree.
Materials and methods: NET cells were stained with red fluorescent dye and injected in the proximity of the developing sub intestinal vessel (SIV) plexus in Tg(fli1:EGFP)y1 embryos. The vasoproliferative response has been detected by both fluorescence microscopy and alkaline phosphatase staining at 24–48 hours post injection.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Giovanni Vitale
Keywords: zebrafish, NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Öberg K, Califano A, Strosberg J, Ma S, ...
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1795 Results from a Phase 2, Open-Label, Multicenter, Randomized Study of the Novel, Octreotide (Oct) Subcutaneous (SC) Depot Formulation in Patients with Functioning Neuroendocrine Tumors (NETs) and Acromegaly Previously Treated with Long-Acting Octreotide
Introduction: Oct sc depot is a novel, ready to use formulation administered via a thin needle.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Marianne Pavel
#1883 Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression
Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Professor Mark Kidd
Keywords: NET